Saatja: "ECDC respiratory viruses" <
[email protected]>
Saaja: "Indra Alexander" <
[email protected]>, "Apfalter Petra" <
[email protected]>, "Wesley.Mattheus" <
[email protected]>, "steven.vangucht" <
[email protected]>, "ivanoov" <
[email protected]>, "stefka.krumova" <
[email protected]>, "ljiljana.zmak" <
[email protected]>, "selma.bosnjak" <
[email protected]>, "Ivana Ferenčak" <
[email protected]>, "m.mendris" <
[email protected]>, "Fani Theophanous" <
[email protected]>, "dpieridou" <
[email protected]>, "ckaragiannis" <
[email protected]>, "Barbora Macková" <
[email protected]>, "pavla.krizova" <
[email protected]>, "Kristina Træholt Franck" <
[email protected]>, "Eva Møller Nielsen" <
[email protected]>, "Salmenlinna Saara" <
[email protected]>, "Savolainen-Kopra Carita" <
[email protected]>, "Mathieu TOURDJMAN" <
[email protected]>, "CASTRO-ALVAREZ Javier" <
[email protected]>, "mankertza" <
[email protected]>, "WernerG" <
[email protected]>, "Ιωάννα Σπηλιοπούλου" <
[email protected]>,
[email protected], "Judit Henczkó" <
[email protected]>, "Kristjan Orri Helgason" <
[email protected]>, "Hannes Bjarki Vigfússon" <
[email protected]>, "Kirsten Schaffer" <
[email protected]>, "ARHAI HPSC" <
[email protected]>, "annateresa.palamara" <
[email protected]>, "Stefanelli Paola" <
[email protected]>, "gatis.pakarna" <
[email protected]>, "Walser-Domjan Esther" <
[email protected]>, "Visscher Carla" <
[email protected]>, "svajune.muralyte" <
[email protected]>, "Jonas Žvirgždas" <
[email protected]>, "Trung Nguyen" <
[email protected]>, "claire.marantidis-cordina" <
[email protected]>, "christopher.barbara" <
[email protected]>, "Titia Kortbeek" <
[email protected]>, "bettie.voordouw" <
[email protected]>, "Trine Marie LAbée-Lund Normann" <
[email protected]>, "Christine Genevieve Monceyron Jonassen" <
[email protected]>, "Karoline Bragstad" <
[email protected]>, "Gierczyński Rafał" <
[email protected]>, "a.skoczynska" <
[email protected]>, "Helena Cortes Martins" <
[email protected]>, "Jorge Machado" <
[email protected]>, "Raluca Gatej" <
[email protected]>, "teodora.vremera" <
[email protected]>, "edita.staronova" <
[email protected]>, "lucia.madarova" <
[email protected]>, "Tjaša Žohar Čretnik" <
[email protected]>, "Andrej Steyer" <
[email protected]>, "katarina.prosenc" <
[email protected]>, "ijado" <
[email protected]>, "Horacio Gil Gil" <
[email protected]>, "sara.byfors" <
[email protected]>, "Andreas.Brave" <
[email protected]>, "Költringer Fiona" <
[email protected]>, "monika.redlberger" <
[email protected]>, "Claire Brugerolles" <
[email protected]>, "Nathalie Bossuyt" <
[email protected]>, "Ivelina Trifonova" <
[email protected]>, "korsun" <
[email protected]>, "maja.ilic" <
[email protected]>, "goranka.petrovic" <
[email protected]>, "Stalo Zani" <
[email protected]>, "Christopher Haralambous" <
[email protected]>, "m.mendris" <
[email protected]>, "Despo Constantinou" <
[email protected]>, "Tonia Adamidi" <
[email protected]>, "Helena Jirincova" <
[email protected]>, "Jan Kynčl" <
[email protected]>, "Hanne-Dorthe Emborg" <
[email protected]>, "Ramona Trebbien" <
[email protected]>, "Julia Geller" <
[email protected]>, "olga.sadikova" <
[email protected]>, "Hanna Nohynek" <
[email protected]>, "Niina Ikonen" <
[email protected]>, "Anna MAISA" <
[email protected]>, "Sibylle BERNARD-STOECKLIN" <
[email protected]>, "PARENT Isabelle" <
[email protected]>, "budas" <
[email protected]>, "haasw" <
[email protected]>, "k.papadima" <
[email protected]>, "a.andreopoulou" <
[email protected]>, "molnar.zsuzsanna" <
[email protected]>, "Agnes Danielisz" <
[email protected]>, "Brynja Ármannsdóttir" <
[email protected]>, "Guðrún Erna Baldvinsdóttir" <
[email protected]>, "Kamilla Sigríður Jósefsdóttir - Landl" <
[email protected]>, "Lisa Domegan" <
[email protected]>, "Eve Robinson" <
[email protected]>, "Puzelli Simona" <
[email protected]>, "Mateo Urdiales Alberto" <
[email protected]>, "Karīna Venediktova" <
[email protected]>, "Walser-Domjan Esther" <
[email protected]>, "Visscher Carla" <
[email protected]>, "Ginreta Megelinskienė" <
[email protected]>, "Greta Gargasienė" <
[email protected]>, "svajune.muralyte" <
[email protected]>, "Joël Mossong" <
[email protected]>, "Gérard Scheiden" <
[email protected]>, "Lautier Elaine at Health Regulation" <
[email protected]>, "Melillo Tanya at Health Regulation" <
[email protected]>, "Rianne van Gageldonk-Lafeber" <
[email protected]>, "Adam Meijer" <
[email protected]>, "Trine Hessevik Paulsen" <
[email protected]>, "Hungnes, Olav" <
[email protected]>, "Paradowska-Stankiewicz Iwona" <
[email protected]>, "Pedro Ferreira" <
[email protected]>, "cristina.barbara" <
[email protected]>, "rodica.popescu" <
[email protected]>,
[email protected], "edita.staronova" <
[email protected]>, "ivan.bakoss" <
[email protected]>, "maja.socan" <
[email protected]>, "eva.grilc" <
[email protected]>, "Susana Monge Corella" <
[email protected]>, "Francisco Pozo Sanchez" <
[email protected]>, "lena.dillner" <
[email protected]>, "anneli.carlander" <
[email protected]>
Teema: To NFPs for action: Invitation to participate in technical meeting – Public health laboratory preparedness for respiratory infections (ECDC)
Kuupäev: 2025-02-07 16:31
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
To: National Focal Points for Viral Respiratory Diseases, National
Focal Points for Microbiology
Cc: National Coordinators, Operational Contact Points for COVID-19 and
influenza (Microbiology)
Dear colleagues,
We are reaching out regarding a study that RAND Europe is conducting on the
preparedness of public health laboratories for respiratory infectious
diseases, commissioned and funded by the European Centre for Disease
Prevention and Control (ECDC). We are now organising a technical meeting
related to that study together with RAND Europe. This study is looking at
challenges public health laboratories faced during the COVID-19 pandemic,
how they were resolved, how to sustain advances made during the pandemic,
and ways to improve long-term preparedness in public health laboratories for
future respiratory infections.
As part of this study, RAND Europe and ECDC will be conducting a technical
meeting on Tuesday 18th of March from 10am-3pm CET (9am -2pm GMT). This
technical meeting is organised to gather further insights from the countries
on laboratory preparedness following the survey and interviews that were
conducted in December 2024. During the meeting participants will learn about
initial findings from this study, based on a literature review and data
collection from public health contact points across EU/EEA countries.
Participants will be asked to reflect on findings, provide feedback, and
discuss views with facilitators and other participants. Topics of discussion
will include the effectiveness of different solutions implemented during the
pandemic, strategies to sustain advances and measures improve preparedness
in public health laboratories.
Two representants per EU/EEA Member State are being invited to partake in
the meeting alongside wider public health stakeholders (e.g. from the
European Commission, ECDC). The participants could be the people who
answered the survey or who were interviewed, or other people among the
official contact points (NFPs, NMFP, OCPs). We would be grateful if, as NFP
or NMFP, you could evaluate who, among yourselves and the Operational
Contact Points for COVID-19 and influenza (Microbiology), would be best
suited to represent your country and to contribute to the discussions during
this meeting. The meeting will take approximately 5 hours, including a
1-hour lunch break. Due to the limited number of participants we can
accommodate, we kindly request that you discuss the topic with colleagues as
needed in order to be able to participate in conversation during the day of
the event.
More information about the content of the meeting can be find in in the
attached Participant Information Sheet. The preliminary agenda is also
available for your information at the end of this email. If you have any
questions about the meeting or the study, please contact the ECDC or RAND
Europe teams.
We are thanking you in advance for taking the time to consider this request.
The nominations should be sent to ECDC at
[email protected]
<mailto:
[email protected]> and cc to RAND Europe (Saoirse
Moriarty at
[email protected] <mailto:
[email protected]> ;
Katie Sykes at
[email protected] <mailto:
[email protected]> ) by 17
February 2025.
Best regards,
The ECDC Respiratory Viruses and Legionella team
and Sarah Parkinson on behalf of RAND Europe
--
Preliminary Agenda of the 18th March’s technical meeting:
Time (CET)
Agenda item
10-10:15
Welcome and introductions
10:15-10:45
Preliminary findings
10:45-11:10
Plenary 1 – Reflections on findings
11:10-12:00
Breakout 1 – Challenges and solutions
12:00-1:00
Lunch break
1:00-2:00
Breakout 2 – Sustaining advances and improving preparedness
2:00-2:10
Plenary 2 - Feedback from breakout rooms
2:10-2:50
Plenary 3 - Prioritisation of lessons from COVID-19
2:50-3:00
Next steps and close
European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00
<https://www.ecdc.europa.eu/> www.ecdc.europa.eu
Follow ECDC on:
<http://www.facebook.com/ECDC.EU>
<https://bsky.app/profile/ecdc.europa.eu>
<http://www.linkedin.com/company/ecdc>
<http://www.youtube.com/user/ECDCchannel>
<https://www.instagram.com/ecdc.eu>
<https://www.threads.net/@ecdc.eu>
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly
requested, to, consecutively, refrain from disclosing its content to any
third party, delete it and inform its sender of the erroneous transmittal.
Participant information sheet You are being invited to take part in a technical meeting as part of research into the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious diseases . This meeting is part of a study commissioned by the European Centre for Disease Prevention and Control (ECDC) to RAND Europe . Before you decide to partake in this technical meeting , it is important for you to understand why this study is being done and what it will involve. Please take time to read the following information carefully , and a sk us if there is anything that is not clear or if you would like more information. Study aims The purpose of this study is to provide evidence to ECDC and key stakeholders in public health around how public health laboratories can be more prepared and resilient in the face of future public health challenges related to respiratory infectious diseases. The guiding research questions for this study are: What were the main challenges public health laboratories faced during the COVID-19 pandemic? What solutions were implemented by public health laboratories to address these challenges? What were the impacts and implications of the solutions implemented by public health laboratories? What is necessary to sustain the advances made during the COVID-19 pandemic in public health laboratory preparedness? How can the lessons learned during the COVID-19 pandemic be utilised to enhance public health laboratory preparedness for other respiratory infectious diseases and potential new pandemics? What long-term strategies should be developed to ensure public health laboratories remain resilient and adaptable in the face of future public health threats? Participation details We have invite d you to participate in a technical meeting to inform our understanding of the challenges that public health laboratories faced during the COVID-19 pandemic and how to make these laboratories more prepared for future public health threats related to respiratory infectious disease . We are interested to learn from your professional knowledge and experience as a stakeholder in this field. Your participation in this would be invaluable. If you decide to take part in the technical meeting , a member of the research team will provide further details about the meeting , including a short 2-4 page briefing . The meeting will be conducted via an online platform (Microsoft Teams) on 18 th March 2025, from 10am-3pm CET. It is expected to last 5 hours , including a 1 hour lunch break , and will include a short presentation from the research team, along with small group and plenary discussions . Before and after the meeting, you will have the chance to provide additional views via an online consultation form. You can respond to this online consultation whether you participate in the technical meeting or not. Do I have to take part? No, it is your choice whether to participate or not. You can also withdraw from the project even after you have agreed to take part without giving a reason. You can withdraw up to two weeks after you have participated in the meeting , and there are no consequences for withdrawing. If you do decide to withdraw, your personal data will be destroyed and will not be used in analysis or reporting. As notes will be taken in aggregate, however, it may not be possible to remove all of your individual contributions from our notes. If you do wish to withdraw after the meeting please contact the project manager, whose details are given at the end of this participant information sheet. Our researchers are happy to discuss any concerns you might have before, during or after the meeting to ensure that you are comfortable with the way that we will use and report the comments you make. Are there possible disadvantages of taking part? All information collected from the technical meeting will be reported in aggregate, and no one besides those in the meeting will know what you individually contributed or said during the meeting . We will not use your name or any other information that could be used to identify you in any publications from the study. We will remove any potentially identifiable information, including names of employers , individuals and specific roles within organisations. We will also confirm any direct (anonymous) quotes, should these be used in the report. However, we cannot entirely remove the possibility that readers may identify you , and we cannot guarantee that other participants keep information confidential (although we will request this at the start of the meeting) . What will happen to the results of the study? We will produce a publicly available report with the results of the study, which will be published by ECDC, and in an academic journal article. We will also publish our findings on the RAND Europe websit e. How will the information that I share be kept confidentially? We will ask your permission to digitally record the meeting . Recording ensures that we capture your comments and perspectives accurately. Detailed notes will be taken of the meeting , and the recording will be referenced as needed . Everything that you say will be treated confidentially and will only be seen by members of the research team , ECDC and other participants of the meeting . We may use things that you have said in the meeting in our reports and other outputs from the evaluation, but we will not use your name or mention any details by which you could be identified. Data will be held on a secure server. Back-ups taken for disaster recovery purposes will be encrypted and stored in a secure offline site. The data linking your identity to the technical meeting will be stored for one year after completion of the project and then destroyed. Data p rotection All data collection and processing will adhere to GDPR, supported by RAND Europe’s ISO27001 certification. RAND Europe have an in-house team, a dedicated Data Protection Officer, an Ethics Advisory Group and an ISO standards committee to ensure compliance. All discussions and materials from meeting will be treated confidentially . If you would like further information about how the data from this meeting is being used, please contact RAND Europe’s Data Protection officer at
[email protected] . Contact for further information Please contact
[email protected] or
[email protected] i f you have any questions about the study or the technical meeting . If you would like to take part in the meeting , then please respond to the invitation sent by email. Thank you for considering participating in the technical meeting .